BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
BTIG analyst Jeet Mukherjee reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $26 price target.
BTIG analyst Jeet Mukherjee reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $26 price target.
